An ongoing dialogue on HIV/AIDS, infectious diseases,
2 Responses to “Ritonavir Tablets: Any Experience Out There Yet?”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Pulmonary Mucormycosis February 12, 2026A 49-year-old man with acute myeloid leukemia was evaluated for prolonged neutropenic fever. On examination, there were crackles at the lung bases. CT of the chest revealed a reversed halo sign.
- Mucormycosis February 12, 2026Mucormycosis is a rapidly progressive, invasive fungal infection that causes severe disease. The latest epidemiologic data, risk factors, diagnostic strategies, and treatment approaches are reviewed.
- A Pediatrician’s Dilemma — Pushing Back against CDC Guidance in the Exam Room February 12, 2026When a mother cites the CDC as her source of dangerous misinformation about vaccines, her child’s pediatrician struggles: how hard can a doctor push back without destroying the trust built over a lifetime?
- Adenoviral Inciting Antigen and Somatic Hypermutation in VITT February 12, 2026VITT is caused by a somatic hypermutation of an anti–adenovirus pVII antibody that generates more avid binding of platelet factor 4 than of adenovirus pVII, its original target, which results in platelet activation.
- Dengue Suppression by Male Wolbachia-Infected Mosquitoes February 11, 2026In this report from Singapore, the release of wolbachia-infected, irradiated male Aedes aegypti mosquitoes resulted in a reduction in the vector population and in the risk of dengue infection.
- Pulmonary Mucormycosis February 12, 2026
We have been using generic RTV tablet since 2-3 years in India and all the capsules have been withdrawn since then. The tolerance is good
Sanjay, thanks for the comment. I wonder how your generic ritonavir compares with the version now licensed in the USA.